Association between SFRP promoter hypermethylation and different types of cancer: A systematic review and meta‑analysis
- Authors:
- Jun Yu
- Yang Xie
- Mengying Li
- Fenfang Zhou
- Zhenyang Zhong
- Yuting Liu
- Feng Wang
- Jian Qi
-
Affiliations: Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Nephrology, Xingguo County People's Hospital, Ganzhou, Jiangxi 344000, P.R. China - Published online on: August 2, 2019 https://doi.org/10.3892/ol.2019.10709
- Pages: 3481-3492
-
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
 |
|
Davies PF, Manduchi E, Jimenez JM and Jiang YZ: Biofluids, cell mechanics and epigenetics: Flow-induced epigenetic mechanisms of endothelial gene expression. J Biomech. 50:3–10. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Takeshima H, Wakabayashi M, Hattori N, Yamashita S and Ushijima T: Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy. Carcinogenesis. 36:192–201. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Agostini M, Enzo MV, Bedin C, Belardinelli V, Goldin E, Del Bianco P, Maschietto E, D'Angelo E, Izzi L, Saccani A, et al: Circulating cell-free DNA: A promising marker of regional lymphonode metastasis in breast cancer patients. Cancer Biomark. 11:89–98. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Qi J, Zhu YQ, Luo J and Tao WH: Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor. World J Gastroenterol. 12:7113–7117. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Nagasaka T, Tanaka N, Cullings HM, Sun DS, Sasamoto H, Uchida T, Koi M, Nishida N, Naomoto Y, Boland CR, et al: Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst. 101:1244–1258. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Li VS, Ng SS, Boersema PJ, Low TY, Karthaus WR, Gerlach JP, Mohammed S, Heck AJ, Maurice MM, Mahmoudi T and Clevers H: Wnt signaling through inhibition of β-catenin degradation in an intact Axin1 complex. Cell. 149:1245–1256. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Surana R, Sikka S, Cai W, Shin EM, Warrier SR, Tan HJ, Arfuso F and Fox SA: Secreted frizzled related proteins: Implications in cancers. Biochim Biophys Acta 1845. 53–65. 2014. | |
|
Takagi H, Sasaki S, Suzuki H, Toyota M, Maruyama R, Nojima M, Yamamoto H, Omata M, Tokino T, Imai K and Shinomura Y: Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma. J Gastroenterol. 43:378–389. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang H, Zhu YQ, Wu YQ, Zhang P and Qi J: Detection of promoter hypermethylation of Wnt antagonist genes in fecal samples for diagnosis of early colorectal cancer. World J Gastroenterol. 20:6329–6335. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chung MT, Sytwu HK, Yan MD, Shih YL, Chang CC, Yu MH, Chu TY, Lai HC and Lin YW: Promoter methylation of SFRPs gene family in cervical cancer. Gynecol Oncol. 112:301–306. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Uhm KO, Lee ES, Lee YM, Kim HS, Park YN and Park SH: Aberrant promoter CpG islands methylation of tumor suppressor genes in cholangiocarcinoma. Oncol Res. 17:151–157. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Lin YW, Chung MT, Lai HC, De Yan M, Shih YL, Chang CC and Yu MH: Methylation analysis of SFRP genes family in cervical adenocarcinoma. J Cancer Res Clin Oncol. 135:1665–1674. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ghasemi A, Rostami S, Chahardouli B, Alizad Ghandforosh N, Ghotaslou A and Nadali F: Study of SFRP1 and SFRP2 methylation status in patients with de novo acute myeloblastic leukemia. Int J Hematol Oncol Stem Cell Res. 9:15–21. 2015.PubMed/NCBI | |
|
Taguchi YH, Iwadate M and Umeyama H: SFRP1 is a possible candidate for epigenetic therapy in non-small cell lung cancer. BMC Med Genomics. 9 (Suppl 1):S282016. View Article : Google Scholar | |
|
Sui C, Ma J, Chen Q and Yang Y: The variation trends of SFRP2 methylation of tissue, feces, and blood detection in colorectal cancer development. Eur J Cancer Prev. 25:288–298. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Q, Huang T, Ye G, Wang B and Zhang X: Methylation of SFRP2 gene as a promising noninvasive biomarker using feces in colorectal cancer diagnosis: A systematic meta-analysis. Sci Rep. 6:333392016. View Article : Google Scholar : PubMed/NCBI | |
|
Chen YZ, Liu D, Zhao YX, Wang HT, Gao Y and Chen Y: Aberrant promoter methylation of the SFRP1 gene may contribute to colorectal carcinogenesis: A meta-analysis. Tumour Biol. 35:9201–9210. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kloten V, Becker B, Winner K, Schrauder MG, Fasching PA, Anzeneder T, Veeck J, Hartmann A, Knüchel R and Dahl E: Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res. 15:R42013. View Article : Google Scholar : PubMed/NCBI | |
|
Suzuki H, Toyota M, Carraway H, Gabrielson E, Ohmura T, Fujikane T, Nishikawa N, Sogabe Y, Nojima M, Sonoda T, et al: Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer. 98:1147–1156. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Moher D, Liberati A, Tetzlaff J and Altman DG; PRISMA Group, : Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol. 62:1006–1012. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Stang A: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zintzaras E and Ioannidis JP: HEGESMA: Genome search meta-analysis and heterogeneity testing. Bioinformatics. 21:3672–3673. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Brinkhuizen T, van den Hurk K, Winnepenninckx VJ, de Hoon JP, van Marion AM, Veeck J, van Engeland M and van Steensel MA: Epigenetic changes in basal cell carcinoma affect SHH and WNT signaling components. PLoS One. 7:e517102012. View Article : Google Scholar : PubMed/NCBI | |
|
Stoehr R, Wissmann C, Suzuki H, Knuechel R, Krieg RC, Klopocki E, Dahl E, Wild P, Blaszyk H, Sauter G, et al: Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest. 84:465–478. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Sun J, Chen Z, Zhu T, Yu J, Ma K, Zhang H, He Y, Luo X and Zhu J: Hypermethylated SFRP1, but none of other nine genes ‘informative’ for western countries, is valuable for bladder cancer detection in Mainland China. J Cancer Res Clin Oncol. 135:1717–1727. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Wang H, Bu R, Fei X, Zhao C and Song Y: Methylation and aberrant expression of the Wnt antagonist secreted Frizzled-related protein 1 in bladder cancer. Oncol Lett. 4:334–338. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Veeck J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B, Galm O, Camara O, Dürst M, Kristiansen G, et al: Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene. 25:3479–3488. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Yang B, Du Z, Gao YT, Wang YJ, Jing X and Bai T: Identification and validation of specific methylation profile in bile for differential diagnosis of malignant biliary stricture. Clin Biochem. 43:1340–1344. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Caldwell GM, Jones C, Gensberg K, Jan S, Hardy RG, Byrd P, Chughtai S, Wallis Y, Matthews GM and Morton DG: The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res. 64:883–888. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Dhir M, Montgomery EA, Glöckner SC, Schuebel KE, Hooker CM, Herman JG, Baylin SB, Gearhart SL and Ahuja N: Epigenetic regulation of WNT signaling pathway genes in inflammatory bowel disease (IBD) associated neoplasia. J Gastrointest Surg. 12:1745–1753. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Patai ÁV, Valcz G, Hollósi P, Kalmár A, Péterfia B, Patai Á, Wichmann B, Spisák S, Barták BK, Leiszter K, et al: Comprehensive DNA methylation analysis reveals a common ten-gene methylation signature in colorectal adenomas and carcinomas. PLoS One. 10:e01338362015. View Article : Google Scholar : PubMed/NCBI | |
|
Salehi R, Mohammadi M, Emami MH and Salehi AR: Methylation pattern of SFRP1 promoter in stool sample is a potential marker for early detection of colorectal cancer. Adv Biomed Res. 1:872012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang W, Bauer M, Croner RS, Pelz JO, Lodygin D, Hermeking H, Stürzl M, Hohenberger W and Matzel KE: DNA stool test for colorectal cancer: Hypermethylation of the secreted frizzled- related protein-1 gene. Dis Colon Rectum. 50:1618–1627. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Rawson JB, Manno M, Mrkonjic M, Daftary D, Dicks E, Buchanan DD, Younghusband HB, Parfrey PS, Young JP, Pollett A, et al: Promoter methylation of Wnt antagonists DKK1 and SFRP1 is associated with opposing tumor subtypes in two large populations of colorectal cancer patients. Carcinogenesis. 32:741–747. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Di Domenico M, Santoro A, Ricciardi C, Iaccarino M, Iaccarino S, Freda M, Feola A, Sanguedolce F, Losito S, Pasquali D, et al: Epigenetic fingerprint in endometrial carcinogenesis: The hypothesis of a uterine field cancerization. Cancer Biol Ther. 12:447–457. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Clement G, Braunschweig R, Pasquier N, Bosman FT and Benhattar J: Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus. Oncogene. 25:3084–3092. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ishii T, Murakami J, Notohara K, Cullings HM, Sasamoto H, Kambara T, Shirakawa Y, Naomoto Y, Ouchida M, Shimizu K, et al: Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa. Gut. 56:13–19. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Liu C, Li N, Lu H, Wang Z, Chen C, Wu L, Liu J, Lu Y and Wang F: Circulating SFRP1 promoter methylation status in gastric adenocarcinoma and esophageal square cell carcinoma. Biomed Rep. 3:123–127. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu JB, Qiang FL, Dong J, Cai J, Zhou SH, Shi MX, Chen KP and Hu ZB: Plasma DNA methylation of Wnt antagonists predicts recurrence of esophageal squamous cell carcinoma. World J Gastroenterol. 17:4917–4921. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Meng Y, Wang QG, Wang JX, Zhu ST, Jiao Y, Li P and Zhang ST: Epigenetic inactivation of the SFRP1 gene in esophageal squamous cell carcinoma. Dig Dis Sci. 56:3195–3203. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zou H, Molina JR, Harrington JJ, Osborn NK, Klatt KK, Romero Y, Burgart LJ and Ahlquist DA: Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Int J Cancer. 116:584–591. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng YY, Yu J, Wong YP, Man EP, To KF, Jin VX, Li J, Tao Q, Sung JJ, Chan FK and Leung WK: Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. Br J Cancer. 97:895–901. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Guo Y, Guo W, Chen Z, Kuang G, Yang Z and Dong Z: Hypermethylation and aberrant expression of Wnt-antagonist family genes in gastric cardia adenocarcinoma. Neoplasma. 58:110–117. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kinoshita T, Nomoto S, Kodera Y, Koike M, Fujiwara M and Nakao A: Decreased expression and aberrant hypermethylation of the SFRP genes in human gastric cancer. Hepatogastroenterology. 58:1051–1056. 2011.PubMed/NCBI | |
|
Liu JB, Wu XM, Cai J, Zhang JY, Zhang JL, Zhou SH, Shi MX and Qiang FL: CpG island methylator phenotype and Helicobacter pylori infection associated with gastric cancer. World J Gastroenterol. 18:5129–5134. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao CH, Bu XM and Zhang N: Hypermethylation and aberrant expression of Wnt antagonist secreted frizzled-related protein 1 in gastric cancer. World J Gastroenterol. 13:2214–2217. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Rettori MM, de Carvalho AC, Longo AL, de Oliveira CZ, Kowalski LP, Carvalho AL and Vettore AL: TIMP3 and CCNA1 hypermethylation in HNSCC is associated with an increased incidence of second primary tumors. J Transl Med. 11:3162013. View Article : Google Scholar : PubMed/NCBI | |
|
Ding SL, Yang ZW, Wang J, Zhang XL, Chen XM and Lu FM: Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 21:6317–6328. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Feng Q, Stern JE, Hawes SE, Lu H, Jiang M and Kiviat NB: DNA methylation changes in normal liver tissues and hepatocellular carcinoma with different viral infection. Exp Mol Pathol. 88:287–292. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hua D, Hu Y, Wu YY, Cheng ZH, Yu J, Du X and Huang ZH: Quantitative methylation analysis of multiple genes using methylation-sensitive restriction enzyme-based quantitative PCR for the detection of hepatocellular carcinoma. Exp Mol Pathol. 91:455–460. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Liu JB, Zhang YX, Zhou SH, Shi MX, Cai J, Liu Y, Chen KP and Qiang FL: CpG island methylator phenotype in plasma is associated with hepatocellular carcinoma prognosis. World J Gastroenterol. 17:4718–4724. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Nomoto S, Kinoshita T, Kato K, Otani S, Kasuya H, Takeda S, Kanazumi N, Sugimoto H and Nakao A: Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Br J Cancer. 97:1260–1265. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Shih YL, Shyu RY, Hsieh CB, Lai HC, Liu KY, Chu TY and Lin YW: Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. Cancer. 107:579–590. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Uhm KO, Lee ES, Lee YM, Park JS, Kim SJ, Kim BS, Kim HS and Park SH: Differential methylation pattern of ID4, SFRP1, and SHP1 between acute myeloid leukemia and chronic myeloid leukemia. J Korean Med Sci. 24:493–497. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Pehlivan M, Sercan Z and Sercan HO: sFRP1 promoter methylation is associated with persistent Philadelphia chromosome in chronic myeloid leukemia. Leuk Res. 33:1062–1067. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Shen JZ, Xu CB, Fu HY, Wu DS, Zhou HR and Fan LP: Methylation of secreted frizzled related protein gene in acute leukemia patients in China. Asian Pac J Cancer Prev. 12:2617–2621. 2011.PubMed/NCBI | |
|
Suzuki M, Shigematsu H, Nakajima T, Kubo R, Motohashi S, Sekine Y, Shibuya K, Iizasa T, Hiroshima K, Nakatani Y, et al: Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer. Clin Cancer Res. 13:6087–6092. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshino M, Suzuki M, Tian L, Moriya Y, Hoshino H, Okamoto T, Yoshida S, Shibuya K and Yoshino I: Promoter hypermethylation of the p16 and Wif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers. Int J Oncol. 35:1201–1209. 2009.PubMed/NCBI | |
|
Zhang YW, Miao YF, Yi J, Geng J, Wang R and Chen LB: Transcriptional inactivation of secreted frizzled-related protein 1 by promoter hypermethylation as a potential biomarker for non-small cell lung cancer. Neoplasma. 57:228–233. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Wang R, Song H, Huang G, Yi J, Zheng Y, Wan J and Chen L: Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett. 303:21–28. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lee CH, Hung YJ, Lin CY, Hung PH, Hung HW and Shieh YS: Loss of SFRP1 expression is associated with aberrant beta-catenin distribution and tumor progression in mucoepidermoid carcinoma of salivary glands. Ann Surg Oncol. 17:2237–2246. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chim CS, Pang R, Fung TK, Choi CL and Liang R: Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia. 21:2527–2536. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chang Q, Pang JC, Li KK, Poon WS, Zhou L and Ng HK: Promoter hypermethylation profile of RASSF1A, FHIT, and sFRP1 in intracranial primitive neuroectodermal tumors. Hum Pathol. 36:1265–1272. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Shabanah OA, Hafez MM, Hassan ZK, Sayed-Ahmed MM, Abozeed WN, Alsheikh A and Al-Rejaie SS: Methylation of SFRPs and APC genes in ovarian cancer infected with high risk human papillomavirus. Asian Pac J Cancer Prev. 15:2719–2725. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Su HY, Lai HC, Lin YW, Chou YC, Liu CY and Yu MH: An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int J Cancer. 124:387–393. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Bu XM, Zhao CH, Zhang N, Gao F, Lin S and Dai XW: Hypermethylation and aberrant expression of secreted frizzled-related protein genes in pancreatic cancer. World J Gastroenterol. 14:3421–3424. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Awakura Y, Nakamura E, Ito N, Kamoto T and Ogawa O: Methylation-associated silencing of SFRP1 in renal cell carcinoma. Oncol Rep. 20:1257–1263. 2008.PubMed/NCBI | |
|
Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, et al: Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res. 13:4740–4749. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clarke N, Brown M, Kishida T, Yao M, Latif F and Maher ER: Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene. 29:2104–2117. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Urakami S, Shiina H, Enokida H, Hirata H, Kawamoto K, Kawakami T, Kikuno N, Tanaka Y, Majid S, Nakagawa M, et al: Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res. 12:6989–6997. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Babaei H, Mohammadi M and Salehi R: DNA methylation analysis of secreted frizzled-related protein 2 gene for the early detection of colorectal cancer in fecal DNA. Niger Med J. 57:242–245. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Bagci B, Sari M, Karadayi K, Turan M, Ozdemir O and Bagci G: KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients. Cancer Biomark. 17:133–143. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chang E, Park DI, Kim YJ, Kim BK, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, et al: Detection of colorectal neoplasm using promoter methylation of ITGA4, SFRP2, and p16 in stool samples: A preliminary report in Korean patients. Hepatogastroenterology. 57:720–727. 2010.PubMed/NCBI | |
|
Huang ZH, Li LH, Yang F and Wang JF: Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J Gastroenterol. 13:950–954. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Leung WK, To KF, Man EP, Chan MW, Hui AJ, Ng SS, Lau JY and Sung JJ: Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am J Gastroenterol. 102:1070–1076. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Lu H, Huang S, Zhang X, Wang D, Zhang X, Yuan X, Zhang Q and Huang Z: DNA methylation analysis of SFRP2, GATA4/5, NDRG4 and VIM for the detection of colorectal cancer in fecal DNA. Oncol Lett. 8:1751–1756. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Müller HM, Oberwalder M, Fiegl H, Morandell M, Goebel G, Zitt M, Mühlthaler M, Ofner D, Margreiter R and Widschwendter M: Methylation changes in faecal DNA: A marker for colorectal cancer screening? Lancet. 363:1283–1285. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Park SK, Song CS, Yang HJ, Jung YS, Choi KY, Koo DH, Kim KE, Jeong KU, Kim HO, Kim H, et al: Erratum: Field cancerization in sporadic colon cancer. Gut Liver. 10:9812016. View Article : Google Scholar : PubMed/NCBI | |
|
Pehlivan S, Artac M, Sever T, Bozcuk H, Kilincarslan C and Pehlivan M: Gene methylation of SFRP2, P16, DAPK1, HIC1, and MGMT and KRAS mutations in sporadic colorectal cancer. Cancer Genet Cytogenet. 201:128–132. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tang D, Liu J, Wang DR, Yu HF, Li YK and Zhang JQ: Diagnostic and prognostic value of the methylation status of secreted frizzled-related protein 2 in colorectal cancer. Clin Invest Med. 34:E88–E95. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wang DR and Tang D: Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol. 14:524–531. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yang W, Wang X, Li X, Wang M, Chen X, Wu X, Wang Y, Fan Y and Jin H: The specific methylation characteristics of cancer related genes in Chinese colorectal cancer patients. Tumour Biol. 35:8267–8279. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Song YF, Lu HN, Wang DP, Zhang XS, Huang SL, Sun BL and Huang ZG: Combined detection of plasma GATA5 and SFRP2 methylation is a valid noninvasive biomarker for colorectal cancer and adenomas. World J Gastroenterol. 21:2629–2637. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Samaei NM, Yazdani Y, Alizadeh-Navaei R, Azadeh H and Farazmandfar T: Promoter methylation analysis of WNT/β-catenin pathway regulators and its association with expression of DNMT1 enzyme in colorectal cancer. J Biomed Sci. 21:732014. View Article : Google Scholar : PubMed/NCBI | |
|
Suehiro Y, Okada T, Okada T, Anno K, Okayama N, Ueno K, Hiura M, Nakamura M, Kondo T, Oga A, et al: Aneuploidy predicts outcome in patients with endometrial carcinoma and is related to lack of CDH13 hypermethylation. Clin Cancer Res. 14:3354–3361. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hao XW, Zhu ST, He YL, Li P, Wang YJ and Zhang ST: Epigenetic inactivation of secreted frizzled-related protein 2 in esophageal squamous cell carcinoma. World J Gastroenterol. 18:532–540. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Nishida N, Nagasaka T, Nishimura T, Ikai I, Boland CR and Goel A: Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology. 47:908–918. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao C, Wang L, Zhu L, Zhang C and Zhou J: Secreted frizzled- related protein 2 is epigenetically silenced and functions as a tumor suppressor in oral squamous cell carcinoma. Mol Med Rep. 10:2293–2298. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Perry AS, O'Hurley G, Raheem OA, Brennan K, Wong S, O'Grady A, Kennedy AM, Marignol L, Murphy TM, Sullivan L, et al: Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer. Int J Cancer. 132:1771–1780. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Brebi P, Hoffstetter R, Andana A, Ili CG, Saavedra K, Viscarra T, Retamal J, Sanchez R and Roa JC: Evaluation of ZAR1 and SFRP4 methylation status as potentials biomarkers for diagnosis in cervical cancer: Exploratory study phase I. Biomarkers. 19:181–188. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao C, Bu X, Zhang N and Wang W: Downregulation of SFRP5 expression and its inverse correlation with those of MMP-7 and MT1-MMP in gastric cancer. BMC Cancer. 9:2242009. View Article : Google Scholar : PubMed/NCBI | |
|
Takeda M, Nagasaka T, Dong-Sheng S, Nishie H, Oka T, Yamada E, Mori Y, Shigeyasu K, Morikawa T, Mizobuchi S and Fujiwara T: Expansion of CpG methylation in the SFRP2 promoter region during colorectal tumorigenesis. Acta Med Okayama. 65:169–177. 2011.PubMed/NCBI | |
|
Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P and Vogelstein B: Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science. 256:102–105. 1992. View Article : Google Scholar : PubMed/NCBI |
